Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05030701

Acronym

MYCATRES

Enrollment

Registered

2021-09-01

Start date

2021-04-09

Completion date

2023-10-15

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Mycobacterium, Treatment Side Effects

Keywords

Mycobacterium, cancer, Treatment Side Effects

Brief summary

Non-tuberculous mycobacteria (NTM) are increasingly common and have a poor prognosis: 5-year mortality can reach 40 to 50%, depending on the type of mycobacteria and the immune system of the host involved. Cancer patients are at higher risk of infectious morbidity and mortality, which may be due to disease-related immune dysfunction, immunosuppressive effects of chemotherapy, or long-term placement of a vascular catheter. However, data on the treatment of NTM species that cause infections and the disease characteristics of these pathogens in cancer patients are limited despite the growing cancer population worldwide. Recently, M. avium infections have been described in patients suffering from cancers (hematological or not), in particular in patients receiving checkpoint inhibitors. Although the proportion of M. avium pneumonia in retrospective series is low (0.8-2%), it has been shown that this population is younger, suffers less from sub-pulmonary pathology. (indicating immunosuppression in these patients) but are therefore treated less than non-cancerous subjects. This retrospective study in CHU Amiens is searching on the number of side effects of NTM treatment in two groups (cancerous and no cancerous) to assess the cause of the decrease of NTM treatment in cancerous patients.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age equal or more than 18 years18 * Patients diagnosed by an infection with non-tuberculous mycobacteria according to ATS guidelines. * Patients received the NTM treatment.

Exclusion criteria

* age less than 18 years * Patients diagnosed by NTM without treatment. * Patients with a positive sample of NTM but without infection. * Exclusion of other disorders such as tuberculous.

Design outcomes

Primary

Measure	Time frame	Description
variation of side effects number of non-tuberculous mycobacteria treatment between cancerous and non cancerous patient groups.	3 months	The main objective of this study is to determine the number of side effects of the treatment of non-tuberculous mycobacteria in patients with this infection with or without cancer at the CHU Picardie Amiens.

Countries

France

Outcome results